RNAZ Latest Press Releases

-- October 28, 2026 --

TransCode Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process Intended to Maximize Value of TTX-MC138 and its Oncology Portfolio PRNewswire 4:31 PM

-- October 26, 2026 --

TransCode Therapeutics Presents Phase 1a Clinical Data for TTX-MC138 at ESMO Congress 2026 PRNewswire 7:31 AM

-- October 19, 2026 --

TransCode Therapeutics to Present Phase 1a Clinical Trial Data for TTX-MC138 at ESMO Congress 2026 PRNewswire 8:05 AM

-- October 13, 2026 --

Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer Business Wire 7:30 AM

-- September 28, 2026 --

TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up PRNewswire 8:05 AM

-- September 22, 2026 --

TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-Oncology PRNewswire 8:04 AM

-- September 10, 2026 --

TransCode Therapeutics Announces Leadership Transition PRNewswire 4:10 PM

-- August 31, 2026 --

TransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone Metastasis PRNewswire 8:05 AM

-- June 8, 2026 --

TransCode Therapeutics to Host R&D Webcast on June 18, 2026 PRNewswire 8:04 AM

-- June 3, 2026 --

TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer PRNewswire 8:04 AM

Market Data Delayed 15 Minutes